EGFR and neoplasm: Palliative therapy, including chemotherapy, which is usually platinum based, and traditional anti-tumor monoclonal antibodies (mAbs, e.g. cetuximab) function by targeting molecules on the tumor cell surface (e.g. EGFR), resulting in functional receptor blockade and inhibition of signal transduction [32,33,34].